Table 4.
Current studies on therapeutic utility of CTCs in metastatic breast cancer.
| Trial | Status | Condition | Intervention | Primary endpoint |
|---|---|---|---|---|
| SWOG S0500 NCT00382018 (Phase III) | Active, not recruiting | CTC persistence under chemotherapy | Treatment choice based on clinical and radiological criteria vs. CTC-guided treatment choice | OS |
| CirCe01 NCT01349842 (Phase III) | Recruiting | CTC persistence under chemotherapy | Treatment choice based on clinical and radiological criteria vs. CTC-guided treatment choice | OS |
| STIC-CTC NCT01710605 (Phase III) | Recruiting | HR+/HER2− MBC | Clinicians choice vs. CTC-guided choice between chemotherapy and endocrine therapy | PFS |
| DETECT III NCT01619111 (Phase III) | Recruiting | HER2-negative metastatic BC with HER2-positive CTCs | Standard therapy ± lapatinib | CTC clearance |
| DETECT IV NCT02035813 (Phase II) | Recruiting | HER2-negative metastatic BC with HER2-negative CTCs | Endocrine therapy + everolimus (DETECT IV a) or eribulin (DETECT IV b) | PFS |
| NCT01975142 (Phase II) | Recruiting | HER2-negative metastatic BC with HER2-positive CTCs | T-DM1 | Tumor response rate |